United Therapeutics Corporation
UTHR
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exerciseā¦ read more
Healthcare
Biotechnology
26 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$396.50
Price-1.81%
-$7.30
1Y
Price
Market Cap
$17.932b
Large
Price/Earnings 3y Avg5y Avg
15.5x
Premium
Premium
Financials Overview
Key metrics over the past few years+54.7%
EBITDA Margin+38.8%
Net Profit Margin+16.2%
Free Cash Flow MarginRevenue
$3.078b
+7.0%
1y CAGR+16.9%
3y CAGR+16.4%
5y CAGREarnings
$1.242b
+3.9%
1y CAGR+20.2%
3y CAGR+28.4%
5y CAGREPS
$25.62
+4.0%
1y CAGR+20.1%
3y CAGR+27.4%
5y CAGRBook Value
$7.174b
$7.908b
Assets$734.400m
Liabilities-
DebtDebt to Assets
0.0%
-
Debt to EBITDAFree Cash Flow
$1.071b
-0.9%
1y CAGR+18.8%
3y CAGR+23.8%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company